S-1 as second line for non-small cell lung cancer with preexisting interstitial pneumonia: phase II study. - S-1 as 2nd line for NSCLC with IP

Hamamatsu University School of Medicine0 个研究点目标入组 28 人开始时间: 2016年5月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) deterioration of preexisting interstitial pneumonia within 3 months (acute/sub-acute cases) 2) history of acute exacerbation of preexisting interstitial pneumonia or drug induced lung injury. 3) taking corticosteroids more than 15 mg/day of prednisolon or equal 4) taking immunosuppressant 5) received irradiation to lung within 3 months 6) using home oxygen therapy (HOT) 7) history of treatment with fluorinated pyrimidine 8) contraindicated for S-1 9) symptomatic, unstable brain metastasis 10) with pleural or peritoneal effusions which need to be drainage 11) with watery diarrhea 12) with severe comorbidities considered to be obstacle for anti-cancer therapy. 13) with metachronous or synchronous multiple cancer 14) using flucytosine 15) being pregnant or have an intention to be or make pregnant, or breast feeding. 16) considered as inappropriate to be participant by the primary physician

发起方